3DPCT Combined With CT Guided RISI in the Treatment of Thoracic Malignant Tumors

Thoracic Cancer Clinical Trial

Official title:

Safety and Efficacy of 3D Printing Coplanar Template Combined With CT Guided Radioactive I-125 Seed Implantation in the Treatment of Thoracic Malignant Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05351268
• Other study ID #: BYSY-2022-3DPCT-TC
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2022
• Est. completion date: April 30, 2026

Study information

• Verified date: December 2023
• Source: Peking University Third Hospital
• Contact: Zhe Ji, M.D.
• Phone: 008618710002823
• Email: aschoff[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main technical difficulties in radioactive iodine-125 seed implantation (RISI) lie in the complexity of operation and the control of operation quality. The current data shows that under the combined guidance of 3D-printing template and CT, the accuracy of RISI has been significantly improved, and the actual target dose could meet the design requirements of preoperative plan. At present, 3D printing templates (3DPT) are divided into non-coplanar templates (3DPNCT) and coplanar templates (3DPCT). In clinical practice, due to the complex technical requirements, high production cost and long printing time of 3DPNCT, a considerable number of patients can also complete the treatment with 3DPCT. Moreover, compared with 3DPNCT, 3DPCT has the advantages of accurate needle path control, fast needle path adjustment, convenient for intraoperative real-time optimization, without waiting for printing time, easy for doctors to master, lower cost than 3DPNCT, and easy to carry out at the grass-roots level. Therefore, this study intends to explore 3DPCT technology to further clarify: (1) the accuracy of 3DPCT assisted CT guided RISI in the treatment of thoracic malignant tumors; (2) the short-term efficacy and toxicity of 3DPCT assisted CT guided RISI in the treatment of thoracic malignant tumors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Pathological diagnosis of malignant tumor of chest, lesion diameter less than 7 cm.
• There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by early treatment.
• No bleeding tendency, anticoagulant therapy and / or antiplatelet coagulation drugs should be stopped for at least 1 week before treatment.
• No serious or uncontrolled underlying diseases (such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction) are found.
• There is a suitable puncture path, and the therapeutic dose is expected to be achieved.
• KPS > 70, expected to tolerate puncture / seed implantation, and expected survival time greater than 3 months.

Exclusion Criteria:

• Severe impairment of lung function (such as FEV1 < 40% predicted value, FVC < 50% predicted value, DLCO < 40% predicted value).
• High risk of skin invasion and ulceration at the puncture site before treatment.
• There is a large range of liquefaction and necrosis in the lesion, and the expected seed distribution would be poor.
• Pregnant women, lactating women and mentally ill patients.
• The patient with poor compliance and unable to complete the treatment.
• Other conditions of the researchers who think it is not suitable to participate in this clinical trial.

Related Conditions & MeSH terms

• Neoplasms
• Thoracic Cancer

Intervention

Radiation:
• Radioactive seed brachytherapy
The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Local progression free survival	The time from the date of SBRT to the date of local recurrence or death or the date of last observation.	From the beginning of the treatment to 2 years after the treatment.
Primary	Incidence of adverse events	The adverse events are evaluated by the common terminology criteria for adverse events (CTCAE). The rate of each adverse event will be measured.	From the beginning of the treatment to 2 years after the treatment.
Secondary	Overall survival	The time from the date of seeds implantation to the date of death from any cause or the date of last observation.	From the beginning of the treatment to 2 years after the treatment.